We are thrilled to announce that our client, iBio, a leading provider of plant-based biotechnology for developing and manufacturing biological products, was successful in its application of its proprietary technologies and achieved the first milestone in its commercial development agreement with AzarGen Biotechnologies of South Africa.
“We focus on addressing the consequences of preterm birth with a special emphasis on surfactant replacement therapy in low-income countries. This successful milestone result has set the pace for scale-up production and elevated the sense of urgency for pre-clinical development,” said Dr. Mauritz Venter, CEO of AzarGen. “We are supported by an experienced team of advisors at AzarGen and iBio. We expect that our product will be clinically superior to current animal-derived and synthetic peptide surfactants. We believe collaboration with iBio, will advance AzarGen’s product development significantly.”
iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The Company also offers proprietary products and product licenses to others based on its proprietary technologies, including its advanced plant-based gene expression and protein production platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines.
You can read the full press release on their website.